One Mark, Two Markets: What Britain's CE Decision Means for Market Access

On 21 October 2026, the UK government answered the question every medical device manufacturer with European ambitions had been pricing in for years: will Britain keep accepting the CE mark, or will it force everyone through a separate domestic approval? The answer: the CE mark stays. Medical devices and in vitro diagnostics certified under the EU's Medical Device Regulation and IVD Regulation will continue to be recognised in Great Britain on a long-term basis — indefinitely. No duplicate approval for devices already cleared for the EU market.

This is the end of a post-Brexit limbo that had manufacturers running two market-access tracks — one for the EU, one for a Britain that might eventually demand its own. For CE-marked products, that second track is now effectively closed. Your European conformity work buys you two markets, not one.

1. The scale of what was at stake

More than 90% of medical devices registered for use in Great Britain already carry a CE mark, according to the government. The consultation that produced this decision — open from 16 February to 10 April 2026 — drew 1,056 responses from patients, healthcare organisations, industry and others.

Had Britain required a separate domestic route for EU-approved devices, it would have created a regulatory bottleneck directly in the NHS supply chain. Insulin pumps, replacement joints, diagnostic tests, surgical equipment — the government named them explicitly — would have faced re-assessment delays. For manufacturers, the cost would have been redundant certification work for a single market. The decision to recognise CE long-term is, at its core, a supply-chain decision dressed as regulatory policy.

2. The CE mark is a ticket, not a pass

Recognition is not deregulation. The government's response leaves three UK obligations firmly in place: appointment of a UK responsible person, MHRA registration, and post-market surveillance. The MHRA will continue to oversee every device on the UK market — monitoring safety through the Yellow Card scheme, sharing safety information with international partners, and taking enforcement action where needed.

This matters for how you budget market entry. CE recognition removes the assessment cost. It does not remove the vigilance cost. UKRP representation, registration, and a functioning post-market surveillance system are operating requirements of the British market, not optional extras.

3. The MDD clock didn't stop — it just got aligned

The indefinite recognition applies to certificates under the newer EU MDR 2017/745 and IVDR 2017/746. Devices still sitting on legacy EU MDD certificates don't get a permanent British reprieve: Great Britain's transitional arrangements for MDD-compliant devices will align with the EU timelines — which end on 31 December 2027 for Class III and implantable Class IIb devices, and on 31 December 2028 for the remaining legacy classes.

There is no British escape hatch from the European legacy-device sunset. If your transition plan assumed that keeping a GB foothold would buy time on MDD devices, it won't. The clock that governs your legacy portfolio is still the EU's. Audit your legacy certificate exposure now, not in 2028.

4. The shortcut that was dropped

The consultation also examined an international reliance route: a streamlined path for devices that carry a higher risk classification in Great Britain than they do in the EU. A majority of respondents opposed it — and it does not appear in the government's stated intent. That route will not go ahead.

This is a narrower point, but it matters for classification strategy. If your device is up-classed under British rules relative to its EU classification, there is no express lane — the full domestic UKCA assessment applies. Classification mismatches between jurisdictions are one of the quieter cost drivers in multi-market entry; the government's decision confirms Britain intends to keep that friction where it exists rather than paper over it.

5. Direction is set; the law still has to follow

One careful reading is warranted: the 21 October announcement is the government's policy response to the consultation. The legislative changes needed to put indefinite recognition into force still have to follow — the response itself does not enact them. Treat this as settled direction with a legislative tail, not as statute.

Meanwhile, the government is modernising the UKCA route itself through a pre-market statutory instrument, and has signalled a future licensing framework better able to respond to advancing technologies, including software and AI medical devices — reflecting the recommendations of the National Commission into the Regulation of AI in Healthcare. Britain is keeping its own lane open, particularly for AI. The UKCA route isn't dead; it's being rebuilt for the products CE pathways handle least comfortably.

What market entrants should take from this

• Plan GB on your EU conformity timeline. CE-marked MDR/IVDR products now carry two-market access. Consolidate your UK entry plan into your European conformity work instead of running parallel tracks.
• Budget for the UK-specific layer. UKRP, MHRA registration, and post-market surveillance are the real cost of British access now. The assessment went away; the vigilance didn't.
• Close out legacy MDD exposure. The EU transition deadlines — 31 December 2027 and 31 December 2028 by class — are the hard edge for legacy devices, in Britain exactly as in the EU.
• Watch the UKCA rebuild, not just the CE recognition. The forthcoming pre-market statutory instrument and the future AI/software licensing framework are where Britain will differentiate itself. If your product is AI-enabled, the interesting market-access story in Britain is the one that hasn't been written yet.

Clearance opens the door. In Britain's case, the door just turned out to be the same one Europe already built.

Sources

• UK Government — “Government confirms indefinite recognition of CE marked medical devices,” GOV.UK news release, 21 October 2026. gov.uk
• UK Government — “Medical devices regulations: targeted consultation on the indefinite recognition of CE marked devices” (full consultation outcome: 1,056 responses; MDR/IVDR scope; MDD alignment; reliance-route outcome; UKRP, MHRA registration and PMS duties). gov.uk
• NovaPharmaNews — “MHRA Keeps CE Marks After 1,056 Responses,” 21 October 2026 (updated 23 October 2026). novapharmanews.com
• PharmEx — “Medicine and device safety updates: 22 October 2026” (legislative changes remain subject to parliamentary process). pharmex.co
• Pharmacy Business / PAGB — “PAGB Backs Continued Recognition of CE-Marked Devices,” October 2026. pharmacy.biz